JacobKingsleyMD(He/Him)

Resident Physician • Ann Arbor, MI

Dermatology Resident

Join to view full profile

Dr. Kingsley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kingsley's full profile

Already have an account?

Office
1500 E Medical Center Dr Tc1910
Ann Arbor, MI 48109
Phone+1 734-615-6874

Education & Training

University of MichiganResidency, Dermatology, 2024 - 2027
University of Nebraska Medical Center College of MedicineInternship, Internal Medicine, 2022 - 2023
University of Nebraska College of MedicineClass of 2022

Certifications & Licensure

MI State Medical License 2024 - 2025
NE State Medical License 2023 - 2024

Clinical Trials

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) Start of enrollment: 2023 Dec 13
Recruiting
Phase 2
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years Start of enrollment: 2021 Jun 30
Recruiting
Phase 3
Safety and Efficacy Study of S-309309 in Obese Adults Start of enrollment: 2023 Jun 21
Active, not recruiting
Phase 2
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years Start of enrollment: 2022 Jul 22
Active, not recruiting
Phase 2, Phase 3
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age Start of enrollment: 2023 Sep 25
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Start of enrollment: 2021 Oct 26
Active, not recruiting
Phase 3
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents Start of enrollment: 2023 Oct 31
Recruiting
Phase 1, Phase 2
Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older Start of enrollment: 2022 Nov 17
Active, not recruiting
Phase 1, Phase 2
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study Start of enrollment: 2022 Dec 16
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
A case of annular erythema of infancy accompanied by elevated tryptase.
Jacob T Kingsley, Erica B Lee, Jennifer L Adams
Pediatric Dermatology. 2022-09-01
Disseminated Histoplasmosis Diagnosed by "Touch Prep".
Jacob Kingsley, Dillon Clarey, Scott R. Lauer, Ryan M. Trowbridge
The American Journal of Dermatopathology. 2020-08-01

Abstracts/Posters

Rapid Improvement of Scleromyxedema Associated with IgG Kappa Monogammopathy after Intravenous Immunoglobulin (IVIG)
Jacob Kingsley, Robert Borucki, Dillon Clarey, Megan Arthur, UNMC GME Research Symposium, 5/4/2022
The Predictive Role of Cutaneous IgA Deposition in Leukocytoclastic Vasculitis with Respect to Renal Involvement: A Systematic Review of the Current Evidence
Rachel Samuelson, Jacob Kingsley, Dillon Clarey, Megan Arthur, American Academy of Dermatology, 9/1/2021

Professional Memberships

Alpha Omega Alpha Honor Medical Society - AOA
Member
American Medical Association - AMA
Member

JacobKingsleyMD(He/Him)

Dr. Kingsley is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.